Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib + Cisplatin + RT in Advanced Head & Neck Carcinoma
NCT00242749Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in head and neck squamous cell carcinoma (HNSCC), sponsored by AstraZeneca. Primary endpoint: Disease-Free Survival at 2 years. Started Dec 2002; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00242749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00242749.